Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study

CompletedOBSERVATIONAL

Enrollment

188,814,085

Participants

Timeline

Start Date

July 22, 2022

Primary Completion Date

May 18, 2023

Study Completion Date

May 18, 2023

Conditions

COVID-19

Interventions

OTHER

ChAdOx1 nCOV-19 vaccine (Vaxzeria)

Used as 2nd booster, 1st booster, or primary series

OTHER

BNT162b2 (Pfizer)

Used as 2nd booster, 1st booster, or primary series.

OTHER

Ad26.COV2.S (Janssen)

Used as 2nd booster, 1st booster, or primary series.

OTHER

CoronaVac (Sinovac)

Used as 2nd booster, 1st booster, or primary series.

Trial Locations (1)

Techtrials Pesquisa e Tecnologia Ltda., São Paulo